Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ursodiol Clear all
Completed Phase 2 Interventional

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

NCT02026401
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
NGM282, Placebo
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Phoenix, Arizona • Coronado, California • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT03602560
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
seladelpar 5-10 mg, seladelpar 10 mg, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

NCT06247735
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
K-808 (Dose A), K-808 (Dose B), Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 18, 2026, 10:15 AM EDT
Recruiting Phase 3 Interventional

Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy

NCT07424677
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Saroglitazar Magnesium 1 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lakewood Rch, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 18, 2026, 10:15 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Trial of High-dose Urso in Primary Sclerosing Cholangitis

NCT00059202
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Ursodeoxycholic Acid, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 18, 2026, 10:15 AM EDT
Not listed Phase 2 Interventional

Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease

NCT00004315
View directory record Official record
Conditions
Cystic Fibrosis, Gastrointestinal Diseases, Cholestasis
Interventions
ursodiol
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
4 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

NCT01865812
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Not applicable Interventional Results available

Clinical Studies on Bile Acids in Barrett's Esophagus

NCT00858858
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Ursodeoxycholic Acid
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment

NCT02967250
View directory record Official record
Conditions
Parkinson Disease
Interventions
ursodeoxycholic acid
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT04620733
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar 10 mg, Placebo, Seladelpar 5 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
40
States / cities
Chandler, Arizona • Little Rock, Arkansas • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

NCT03124108
View directory record Official record
Conditions
Primary Biliary Cholangitis (PBC)
Interventions
Elafibranor 80 mg, Elafibranor 120 mg, Placebo
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 18, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis

NCT03602976
View directory record Official record
Conditions
Hepatic Sarcoidosis, Elevated Alkaline Phosphatase
Interventions
Ursodeoxycholic Acid
Drug
Lead sponsor
Ethan Weinberg
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

NCT06060665
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar 10 mg, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

Ursodiol-Methotrexate for Primary Biliary Cirrhosis

NCT00006168
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Methotrexate
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
20 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

NCT00873275
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET)
Biological · Drug · Genetic + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 18, 2026, 10:15 AM EDT
Withdrawn Phase 2 Interventional

Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis

NCT01141296
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
fenofibrate, placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Miami, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

NCT06383403
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Elafibranor, Placebo
Drug · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
20
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 18, 2026, 10:15 AM EDT
Not listed Phase 1 Interventional

Ursodiol in Huntington's Disease

NCT00514774
View directory record Official record
Conditions
Huntington Disease
Interventions
ursodiol, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Oct 18, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

NCT02244944
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
EZ-Urso combination therapy
Drug
Lead sponsor
Gregory Graf, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

NCT00805805
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Tetrathiomolybdate, Placebo
Drug · Other
Lead sponsor
George Brewer
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 18, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional

Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

NCT00062023
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Acetylsalicylic acid (Aspirin), Sulindac, Ursodiol, Sulindac Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 18, 2026, 10:15 AM EDT
Not listed Not applicable Interventional

Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation

NCT01157780
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease
Interventions
Lovaza (fish oil)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
1 Day to 1 Year
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 18, 2026, 10:15 AM EDT
Terminated Not applicable Interventional

Effects of TUDCA on Endothelial Function in Type 2 DM

NCT03462940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Response, Endothelial Dysfunction
Interventions
Tauroursodeoxycholic acid
Dietary Supplement
Lead sponsor
Boston University
Other
Eligibility
21 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 18, 2026, 10:15 AM EDT
Terminated Phase 2Phase 3 Interventional

The Role of Secondary Bile Acids in Intestinal Inflammation

NCT03724175
View directory record Official record
Conditions
Ulcerative Colitis, Pouchitis
Interventions
ursodiol (ursodeoxycholic acid, UDCA)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 18, 2026, 10:15 AM EDT